• WCLC 2024 Update: Dr. Baohui Han Discusses the DUBLIN-3 and DURABLE Trials

    The 2024 World Conference on Lung Cancer (WCLC) was held in San Diego from September 7-10, featuring major studies from Chinese scholars. Oncology Frontier had the opportunity to interview Dr. Baohui Han from Shanghai Chest Hospital, inviting her to interpret the results of the DUBLIN-3 and DURABLE clinical trials.

  • Hepatology | Association Between Metabolic-Associated Fatty Liver Disease and Subclinical Hypothyroidism in Adolescents

    Subclinical hypothyroidism, previously referred to as mild thyroid dysfunction or impaired thyroid reserve, is increasingly detected due to advancements in thyroid function testing. Research has shown that subclinical hypothyroidism is…

  • Non-KPC Characteristics of Novel BL/BLI Compounds in Pseudomonas aeruginosa

    Resistance Mechanisms of Pseudomonas aeruginosa Compared to Enterobacterales, the resistance mechanisms in Pseudomonas aeruginosa are more frequently regulated by alterations in membrane permeability through porin channels and efflux pump expression.…

  • Liver Cancer Breakthrough Unveiled at ESMO 2024!

    Thrilled to share our interview with Professor Guohong Han about the LEAP-012 study, which could revolutionize liver cancer treatment! Combining TACE with lenvatinib and pembrolizumab is showing incredible results for intermediate-stage liver cancer: 46.8% tumor response rate Progression-free survival boosted from 10 to 14.6 months

  • Exclusive Insights on mHSPC Treatment: Interview with Dr. Fred Saad

    In a recent Media Medic interview, our colleague El Bachir MOURABIT had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival. He also shared promising…

  • Dr. Shahrukh Hashmi: Opening Pandora’s Box, Challenges in Long-Term Monitoring After CAR-T Therapy

    As a shining new star in the medical field, CAR-T cell therapy, while significantly effective, is filled with unknowns much like Pandora’s Box. From successful treatment to long-term monitoring, every step requires meticulous planning. Recently, at the 12th Lu Daopei Hematology Academic Forum, Hematology Frontier had the honor of inviting Dr. Shahrukh Hashmi from the…

  • SOHO 2024 | Dr. Valeria Santini: Imetelstat Demonstrates Durable Efficacy in the Treatment of LR-MDS

    Low-risk myelodysplastic syndromes (LR-MDS) are complex blood disorders characterized by the abnormal proliferation and dysfunction of marrow cells, leading to increased risks of anemia, bleeding, and infection. Although the progression of LR-MDS is relatively slow, the treatment of this disease still faces significant challenges. Existing therapeutic options, such as erythropoiesis-stimulating agents (ESAs) and immunomodulators, may…

  • Shaping the Future of Lung Cancer Care: Dr. Caicun Zhou on IASLC’s 50th Anniversary and the Promise of HARMONi2

    The International Association for the Study of Lung Cancer (IASLC), founded in 1974, has grown into a global organization with over 10,000 members from more than 100 countries and regions. In 2023, Dr. Caicun Zhou from Shanghai Pulmonary Hospital, Tongji University School of Medicine was elected as the IASLC President-Elect for 2023-2025 and will serve…